K V Pharmaceutical Co Cl A (NASDAQOTH:KVPHQ)

CAPS Rating: 2 out of 5

Develops advanced drug delivery technologies which enhance the effectiveness of new therapeutic agents, existing pharmaceutical products and prescription nutritional products.

Results 1 - 20 of 49 : 1 2 3 Next »

Recs

1
Member Avatar 2gud2btrue (68.10) Submitted: 5/17/2012 3:27:09 PM : Outperform Start Price: $0.88 KVPHQ Score: -157.19

Lets hope it will run back to $6 soon...

Recs

1
Member Avatar lookingforanswer (< 20) Submitted: 3/25/2012 1:17:22 PM : Underperform Start Price: $1.35 KVPHQ Score: +147.04

It will not be around for longer than 2012

Recs

1
Member Avatar siri22 (< 20) Submitted: 11/9/2011 1:53:03 AM : Outperform Start Price: $1.65 KVPHQ Score: -165.78

Lttle chinese mix>

Recs

0
Member Avatar Cochuso (< 20) Submitted: 10/27/2011 1:42:59 PM : Outperform Start Price: $1.31 KVPHQ Score: -161.22

Why this stock is not presente in Google Finance

Recs

0
Member Avatar Stockpwner (< 20) Submitted: 8/1/2011 5:13:07 PM : Underperform Start Price: $2.05 KVPHQ Score: +162.08

Sell

Recs

0
Member Avatar robertshrestha (55.99) Submitted: 4/29/2011 9:19:01 AM : Underperform Start Price: $4.07 KVPHQ Score: +152.31

Too much uncertainty right now, still coming under heavy fire, significant price drop on Makena will hurt margins going forward, stock still up quite a bit since FDA approval (even with recent plunge). Too risky for my blood.

Recs

0
Member Avatar numby98 (< 20) Submitted: 4/21/2011 11:56:59 AM : Outperform Start Price: $4.10 KVPHQ Score: -155.07

No doubt ,KV has the exclusive rights to Makena which has FDA approval and Doctors will turn to Makena as their sole recomendation for women who have lost pre-term babies, and are now pregnant...

Recs

0
Member Avatar lancer009 (< 20) Submitted: 4/6/2011 2:59:48 AM : Outperform Start Price: $4.65 KVPHQ Score: -154.93

its just matter of time

Recs

0
Member Avatar ChrisGraley (29.65) Submitted: 4/5/2011 11:37:14 PM : Outperform Start Price: $4.65 KVPHQ Score: -154.93

Alright, I''ve rode this up and then red thumbed it and rode it down. It's priced to be a good choice for the long run again.

Recs

0
Member Avatar samarthyaa (< 20) Submitted: 4/5/2011 9:17:13 PM : Outperform Start Price: $4.65 KVPHQ Score: -154.93

I strongly believe that KV is taking right steps toward the pricing. Makena is a very important drug and will be having a huge user base in coming months. Makena deserves a primium pricing over compound pharmacies drug, and I guess no body has a doubt against it considering the safety and underneath cose involved plus a responsible company behind it. To me, it seems like some of the articles/disucssion is unnecessary and very negatively approached.

I am long on KV.

Recs

0
Member Avatar randomvariable (72.35) Submitted: 4/4/2011 2:21:11 PM : Outperform Start Price: $5.14 KVPHQ Score: -155.87

Rode it up on the FDA approval, getting back in after the lower-than-hoped-for price news. I think it will still move up.

Recs

0
Member Avatar teigman (< 20) Submitted: 3/9/2011 7:22:45 PM : Outperform Start Price: $12.82 KVPHQ Score: -158.45

Makena has amazing potential- On the basis of the New England Jounal of Medicine Article 2003 the drug truly does benefit in preterm labor. Demand is going to be hard to fill. OBs use this drug on a regular basis compounded from pharmacies. It is going to make it a lot easier to dispense to patients. In the end we will help prevent much of the sequela from preterm labor if taken in time. It is truly a breakthrough...

Recs

0
Member Avatar tahoejack (< 20) Submitted: 3/7/2011 7:13:24 PM : Outperform Start Price: $10.38 KVPHQ Score: -157.66

New drug with hot chart a little competition

Recs

0
Member Avatar doctorsynthesis (< 20) Submitted: 2/25/2011 11:36:30 AM : Outperform Start Price: $8.07 KVPHQ Score: -157.53

These guys have a blockbuster on their hands (Makena)....why? ppl have to realize two things: Makena is a huge profit margin drug ($1500 per injection) and it will be covered by all healthcare plans (see below).

While the number of premature births (and thus the market for Makena) may not be as large as for typical blockbuster drugs, the cost to the healthcare system from premature births is disproportionately high. This is what allows Makena to get away with such high margins since $1500 per injection to prevent a premature birth is still way cheaper than the costs of long-term care for premature babies in hospitals. This is money in the bank for K V.

Recs

0
Member Avatar GTcollegekid (39.45) Submitted: 2/21/2011 2:41:21 PM : Outperform Start Price: $4.00 KVPHQ Score: -157.34

just in the United States, about 12.8 percent of babies (more than half a million a year) are born prematurely

Recs

0
Member Avatar Bartwaldon (< 20) Submitted: 2/19/2011 1:02:37 AM : Outperform Start Price: $9.48 KVPHQ Score: -155.90

Kv-A has recently gotten their new drug Makena approved by the FDA which means they now have a "monopoly" on the first drug capable of reducing the risk of premature birth. Premature birth cost the US alone over 26 billion dollars each year... The road to recovery for Kv pharmaceutical looks much brighter and possibly holds an even greater financial future for Kv-a in the coming years.

Recs

1
Member Avatar tgrearden (< 20) Submitted: 2/17/2011 1:20:51 AM : Outperform Start Price: $8.13 KVPHQ Score: -155.49

New Management, New Drug Approval, FDA approval of production processes

Recs

2
Member Avatar mrjig27 (< 20) Submitted: 2/14/2011 3:31:58 PM : Outperform Start Price: $5.80 KVPHQ Score: -155.56

2/14/2011 Happy kV-a day!

Recs

0
Member Avatar paluba (< 20) Submitted: 12/2/2010 5:27:30 AM : Outperform Start Price: $1.75 KVPHQ Score: -161.57

I bought in March of 2010, thinking that the stock can't get any lower. I was wrong, but was in it for the long haul. I've already made a profit, and when Gestiva gets FDA approval, this stock will really take off. I'll sell on the ridiculous jump it gets and make a tidy profit before it falls to realistic levels.

Recs

0
Member Avatar august18 (< 20) Submitted: 10/11/2010 1:17:51 PM : Outperform Start Price: $2.72 KVPHQ Score: -177.49

support price is $2.46

Results 1 - 20 of 49 : 1 2 3 Next »

Featured Broker Partners


Advertisement